Quigley was also featured on CNBC Thursday afternoon. CNBC was reviewing stocks managed by some children (an experiment) and the announcer said some very kind words about the company. Up 10-plus percent yesterday alone.
I think, with the upcoming cold season (thanx El Nino) and the fact that QLGY seems to have a good product and is willing to fight for its reputation, it sounds like a good buy. Currently, it's rated a "speculative buy" (whatever that means -- "yeah, buy it, but maybe not....").
I have included a story about an ABC report about zinc losenges and how they didn't give all the facts about the subject.
Bobby
-------------------------------------
MEDIA ADVISORY: WARNING Re: Cold-Eeze(R): The Quigley Corporation Responds to Conus Medical Feed, News 1 New York (ABC), WISN Milwaukee
PR Newswire, Friday, October 31, 1997 at 17:08
The following was issued on behalf of The Quigley Corporation:
A story which aired on a number of ABC and CBS affiliate stations concerning zinc and its effect on pregnant women is inaccurate, poorly researched, absolutely misleading and based on information that falsely marries The Quigley Corporation's Cold-Eeze(R) zinc lozenges to the story line.
ABC has been advised and agreed to stop its affiliates from using the story pending further investigation.
Do not run this story until you check out the facts first.
The story brought to the attention of the media by a doctor in Wisconsin is based on a 1977 American Journal of Nutrition Letter to the Editor citing a report by the Indian Council on Medical Research in 1975, in which pregnant women took "100 mg. of zinc sulfate thrice daily" during the last trimester of their pregnancies which resulted in three premature births and one stillbirth
in four consecutive subjects.
Cold-Eeze(R), the zinc lozenge manufactured by The Quigley Corporation, in Doylestown, Pennsylvania, contains a different kind of zinc -- zinc gluconate glycine (ZIGG(TM)) -- and each lozenge contains 13.3 mg. It is recommended not to exceed 6 lozenges daily.
Dr. Kurt Hegmann, Assistant Professor, of the Medical College of Wisconsin, who brought this matter to the attention of the media and was featured in the story, says, "The story is misleading, inaccurate and irresponsible." His letter to The Quigley Corporation, on the letterhead of the Medical College of Wisconsin, follows:
The following letter dated October 31, 1997, was sent to the attention of Thomas MacAniff, General Counsel, Quigley Corporation, from Kurt T. Hegmann,MD, MPH, Assistant Professor, Medical College of Wisconsin:
This letter documents the principal points covered in our conversation on the above date regarding a news story on Coldeeze that originated at WISN in Milwaukee, Wisconsin.
First, as evidenced by the Cleveland Clinic study, this medication may reduce symptoms and shorten the duration of the common cold.
Second, the research from India cited in the above taping utilized zinc sulfate and not zinc gluconate (the active ingredient in Coldeeze).
Third, as recommended on the label, the Coldeeze recommended dosing is up to six tablets per day, or about 79.8 milligrams of zinc. This is a level for which there is NO study that has indicated any adverse effect.
Fourth, the use of Coldeeze, which I held up for the videotaping, during the story by WISN, was at the request of the personnel from WISN.
Fifth, I believe that any attempt to portray Coldeeze as being a subject of adverse effects in medical or clinical trials is misleading, inaccurate, and irresponsible.
Should further questions arise, please do not hesitate to contact me. Sincerely,
/s/ Kurt T. Hegmann, MD, MPH
Assistant Professor
CONTACT: Geri Rosman, Karen Goldman, Lois Kaufman, Carrie Thomas or Jodi Devine of INFOCUS, 609-683-9055, for The Quigley Corporation; AFTER 6 P.M., MESSAGES CAN BE LEFT IN THE GENERAL MESSAGE CENTER AND WILL BE ANSWERED WITHIN THE HOUR OR YOU CAN REACH GERI ROSMAN ON CELL PHONE, 908-963-1691, ANYTIME.
SOURCE Quigley Corporation
-0- 10/31/97
/PRNewswire -- Oct. 31/ |
